Confirmed Ebola cases in the Democratic Republic of the Congo have reached 4,053, including 1,850 deaths, according to health authorities tracking an unprecedented Bundibugyo ebolavirus outbreak that has outpaced national response efforts. As investigators examine whether viral mutations are driving the rapid spread, global health agencies are accelerating clinical trials for new vaccines and expanding treatments to curb the second-largest Ebola epidemic in recorded history.
Outbreak Spreads Across 53 Health Zones as Response Lags
The outbreak has expanded across 53 health zones in five provinces, including Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo, according to official data released by Democratic Republic of the Congo authorities. Ituri remains the primary epicenter, accounting for 86.9 percent of all confirmed cases. Alongside 1,850 deaths, the country has recorded 793 recoveries.
Jean Kaseya, director-general of the Africa Centers for Disease Control and Prevention, stated during an online briefing that the reported figures likely underrepresent the true scale of the crisis. Kaseya noted that officials are initiating studies to investigate whether viral mutations are contributing to the severity and rapid growth of the epidemic.
Did you know? This outbreak is caused by the Bundibugyo ebolavirus, marking the largest occurrence of this specific strain in the Democratic Republic of the Congo since the virus was first identified in the country in 1976.
Shifting Toward Community-Led Responses
Health officials report that the primary obstacle to containing the virus is not a lack of funding, but a significant gap in community mobilization. Kaseya emphasized the urgent need to shift toward a community-led response focused on earlier case detection, stronger contact tracing, and accessible testing.
World Health Organization Director-General Tedros Adhanom Ghebreyesus reinforced this strategy following a visit to Kinshasa, stating on social media that community ownership must remain at the heart of the containment effort. Authorities are calling for closer engagement with religious, traditional, women, and youth leaders to support frontline workers.
Expanding Vaccine and Treatment Strategies
While no licensed vaccine or approved specific treatment currently exists for the Bundibugyo ebolavirus, officials are broadening the deployment of existing medical tools. Kaseya announced that health authorities have decided to expand the use of Ervebo—a vaccine licensed against the Zaire ebolavirus species—among populations in Ituri and North Kivu while formal studies continue.
Field observations suggest that individuals previously vaccinated against Zaire ebolavirus who subsequently contracted the Bundibugyo strain developed milder symptoms or survived. According to Kaseya, no deaths have been recorded in the previously vaccinated group, whereas fatalities in the current outbreak have occurred among unvaccinated patients.
Vasee Moorthy, acting lead of the World Health Organization R&D Blueprint, stated during a press Geneva briefing that the agency is reviewing new animal-study data regarding cross-protection from Ervebo. Concurrently, candidate vaccines targeting the Bundibugyo virus are advancing through clinical trials. A candidate developed by the University of Oxford and the Serum Institute of India entered Phase 1 trials in Britain, while a second candidate developed by Moderna is slated to begin Phase 1 testing in Canada.
Essential Components of Ebola Containment
- Active surveillance and laboratory testing
- Case management and infection prevention control
- Safe and dignified burials
- Deep community engagement and frontline worker support
Frequently Asked Questions
What strain of the virus is causing the current outbreak in the Democratic Republic of the Congo?
The outbreak is caused by the Bundibugyo ebolavirus, making it the largest recorded occurrence of this specific strain in the country.
How many cases and deaths have been reported?
According to Democratic Republic of the Congo authorities, confirmed cases have reached 4,053, including 1,850 deaths and 793 recoveries.
Are there approved vaccines for the Bundibugyo ebolavirus?
There is currently no licensed vaccine specifically for the Bundibugyo ebolavirus, but health officials are deploying the Ervebo vaccine—designed for the Zaire strain—due to observed cross-protection benefits.
Which clinical trials are currently underway?
Phase 1 clinical trials are underway for new candidate vaccines developed by the University of Oxford alongside the Serum Institute of India, and by Moderna.
Stay Informed on Global Health Developments
Subscribe to our newsletter for verified updates on international health emergencies, vaccine trials, and outbreak responses.
Worth a look